Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
- Matej Orešič1⇑,
- Peddinti Gopalacharyulu1,
- Juha Mykkänen2,3,
- Niina Lietzen1,
- Marjaana Mäkinen2,3,
- Heli Nygren1,
- Satu Simell2,3,
- Ville Simell2,3,
- Heikki Hyöty4,5,
- Riitta Veijola6,
- Jorma Ilonen7,8,
- Marko Sysi-Aho1,
- Mikael Knip9,10,11,12,
- Tuulia Hyötyläinen1 and
- Olli Simell2,3
- 1VTT Technical Research Centre of Finland, Espoo, Finland
- 2Department of Pediatrics, University of Turku, Turku, Finland
- 3Hospital District of Southwest Finland, Turku, Finland
- 4Department of Virology, School of Medicine, University of Tampere, Tampere, Finland
- 5Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland
- 6Institute of Clinical Medicine, University of Oulu, Oulu, Finland
- 7Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland
- 8Immunogenetics Laboratory, University of Turku, Turku, Finland
- 9Children’s Hospital, University of Helsinki, Helsinki, Finland
- 10Helsinki University Central Hospital, Helsinki, Finland
- 11Department of Pediatrics, Tampere University Hospital, Tampere, Finland
- 12Folkhälsan Research Center, Helsinki, Finland
- Corresponding author: Matej Orešič, .
Previous studies show that children who later progress to type 1 diabetes (T1D) have decreased preautoimmune concentrations of multiple phospholipids as compared with nonprogressors. It is still unclear whether these changes associate with development of β-cell autoimmunity or specifically with clinical T1D. Here, we studied umbilical cord serum lipidome in infants who later developed T1D (N = 33); infants who developed three or four (N = 31) islet autoantibodies, two (N = 31) islet autoantibodies, or one (N = 48) islet autoantibody during the follow-up; and controls (N = 143) matched for sex, HLA-DQB1 genotype, city of birth, and period of birth. The analyses of serum molecular lipids were performed using the established lipidomics platform based on ultra-performance liquid chromatography coupled to mass spectrometry. We found that T1D progressors are characterized by a distinct cord blood lipidomic profile that includes reduced major choline-containing phospholipids, including sphingomyelins and phosphatidylcholines. A molecular signature was developed comprising seven lipids that predicted high risk for progression to T1D with an odds ratio of 5.94 (95% CI, 1.07–17.50). Reduction in choline-containing phospholipids in cord blood therefore is specifically associated with progression to T1D but not with development of β-cell autoimmunity in general.
- Received January 30, 2013.
- Accepted April 23, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.